Ming-Whei Yu

Prof. Ming-Whei Yu

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
MYMing-Whei Yu
Ming-Whei Yu
SYShiou-Hwei Yeh
Shiou-Hwei Yeh
PCPei-Jer Chen
Pei-Jer Chen
YLYun-Fan Liaw
Yun-Fan Liaw
CLChih-Lin Lin
Chih-Lin Lin
CCChien-Jen Chen
Chien-Jen Chen
Background: Although chronic infection with hepatitis B virus (HBV) has been established as a cause of hepatocellular carcinoma (HCC), the roles of viral load and HBV genotype remain unclear. Methods: From 1988 through 1992, baseline blood samples were collected from 4841 Taiwanese men who were HBV carriers but had not been diagnosed with HCC. We used real-time polymerase chain reaction assays of plasma DNA samples to quantify HBV DNA levels (a measure of viral load) and determine HBV genotypes for 154 case patients who were diagnosed with HCC during 14 years of follow-up and 316 control subjects. Unconditional logistic regression was used to assess odds ratios (ORs) of HCC for HBV-related factors. All statistical tests were two-sided. Results: The risk of HCC increased with increasing HBV viral load (adjusted OR for the highest versus the lowest quintile of HBV DNA copies/mL = 7.26, 95% confidence interval [CI] = 3.54 to 14.89; Ptrend<.001). Genotype C HBV was associated with an increased risk of HCC compared with other HBV genotypes (adjusted OR = 5.11, 95% CI = 3.20 to 8.18). Both viral load and genotype were positively associated with HCC within 10-year age categories among subjects aged 30 years old to older than 60 years. Genotype C HBV was associated with increased viral load, and associations of HBV genotype and viral load with HCC risk were additive. The adjusted OR of HCC for those carrying genotype C HBV and with viral load in the highest quintile was 26.49 (95% CI = 10.41 to 67.42) compared with HBV carriers with other HBV genotypes and viral load in the lowest two quintiles. Conclusions: Measurements of HBV viral load and genotype may help to define which male HBV carriers aged 30 years or older are at high risk for HCC.

1 October 1997 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
CCChien‐Jen Chen
Chien‐Jen Chen
MYMing-Whei Yu
Ming-Whei Yu
YLYun‐Fan Liaw
Yun‐Fan Liaw

1 June 1997 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MYMing-Whei Yu
Ming-Whei Yu
FHFang-Chi Hsu
Fang-Chi Hsu
ISI-Shyan Sheen
I-Shyan Sheen
CCChia-Ming Chu
Chia-Ming Chu
DLDeng-Yn Lin
Deng-Yn Lin
YLYun-Fan Liaw
Yun-Fan Liaw
The authors conducted a study to assess the importance of underlying liver cirihosis in the development of hepatocellular carcinoma (HCC) and the multifactorial etiology of liver cirrhosis in chronic carriers of hepatitis B virus (HBV). Between November 1980 and May 1990, all male hepatitis B surface antigen (HBsAg) carriers who routinely attended a clinic for asymptomatic HBV carriers at the Liver Unit of Chang-Gung Memorial Hospital, Taiwan, were enrolled in the study (n = 1,506). The authors used this cohort to investigate prospectively for liver cirrhosis and HCC at 6-month intervals by means of ultrasonography and clinical assessment. There were 16 incident cases of HCC and 89 cases of liver cirrhosis (78 of whom were detected during follow-up) identified after an average follow-up of 7.1 years. Subclinical liver cirrhosis diagnosed by ultrasonography was significantly associated with the risk for HCC (multivariate-adjusted relative risk (RR) = 11.8, 95% confidence interval (CI) 3.9–35.8). By multivariate analysis, the significant risk factors found for liver cirrhosis in HBsAg carriers were age, hepatitis B e antigen (HBeAg) carrier status, chronic hepatitis manifested by sustained elevated serum aminotransferase levels for ≥6 months, cigarette smoking, non-A blood types, and low educational levels. Habitual alcohol drinking was not independently related to liver cirrhosis. However, the risk of liver cirrhosis associated with smoking was more striking among drinkers than nondrinkers (≥20 cigarettes/day vs. nonsmokers: drinkers, RR = 9.3, 95% CI 1.1–78.8; nondrinkers, RR = 1.85, 95% CI 0.98–3.51), which suggests a possible modification effect of alcohol drinking on the liver cirrhosis risk of cigarette smoking. The authors observed synergistic effects on liver cinhosis development for cigarette smoking with HBeAg carrier status and chronic hepatitis. Am J Epidemiol 1997;145:1039-47.

19 July 2000 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MYMing-Whei Yu
Ming-Whei Yu
HCHung-Chuen Chang
Hung-Chuen Chang
YLYun-Fan Liaw
Yun-Fan Liaw
SLShi-Ming Lin
Shi-Ming Lin
SLShou-Dong Lee
Shou-Dong Lee
CCChien-Jen Chen
Chien-Jen Chen
Background: Familial predisposition as a risk factor for hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) carriers has not been thoroughly explored. Methods: The HCC risk associated with having parents and/or siblings with HCC was evaluated by use of a cohort study of 4808 male HBV carriers. A case–control family study was also conducted on data from first-degree relatives of 553 HBV carriers who had newly diagnosed HCC (case subjects) and 4684 HBV carriers without HCC (control subjects). Results: In the cohort study, HBV carriers with a family history of HCC had a multivariate-adjusted rate ratio for HCC of 2.41 (95% confidence interval [CI] = 1.47–3.95) compared with HBV carriers without a family history of HCC. For carriers with two or more affected relatives, the ratio increased to 5.55 (95% CI = 2.02–15.26). Cumulative HCC risk by age 70 years was 235.6 per 1000 (95% CI = 95.3–375.9 per 1000) for HBV carriers with family history compared with 88.9 per 1000 (95% CI = 67.9–109.9 per 1000) for those without. In the case–control family study, first-degree relatives of case subjects were more likely to have HCC (age–sex-adjusted odds ratio [OR] = 2.57; 95% CI = 2.03–3.25) than first-degree relatives of control subjects. The excess risk of HCC among relatives was particularly evident in siblings (sisters—age-adjusted OR = 4.55 [95% CI = 2.22–9.31]; brothers—age-adjusted OR = 3.73 [95% CI = 2.64–5.27]), but it was also observed in parents. The cumulative risk of HCC to age 80 years was 83.0 per 1000 among relatives of case subjects and 42.0 per 1000 among relatives of control subjects. Among relatives of case subjects, the cumulative risk of HCC was greater if the case subjects were diagnosed before age 50 years (two-sided P = .047). Liver cirrhosis was 2.29 (95% CI = 1.68–3.11) times more frequent in relatives of case subjects than in relatives of control subjects. Conclusions: First-degree relatives of patients with HBV-related HCC appear to be at increased risk of HCC and should be considered in the formulation of HCC-screening programs.

11 January 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
JSJing Shen
Jing Shen
SWShuang Wang
Shuang Wang
YZYu-Jing Zhang
Yu-Jing Zhang
MKMaya Kappil
Maya Kappil
HWHui-Chen Wu
Hui-Chen Wu
RSRegina M. Santella
Regina M. Santella
Alterations in DNA methylation frequently occur in hepatocellular cancer (HCC). We have previously demonstrated that hypermethylation in candidate genes can be detected in plasma DNA before HCC diagnosis. To identify, with a genome-wide approach, additional genes hypermethylated in HCC that could be used for more accurate analysis of plasma DNA for early diagnosis, we analyzed tumor and adjacent nontumor tissues from 62 Taiwanese HCC cases using Illumina methylation arrays (Illumina, Inc., San Diego, CA) that screen 26,486 autosomal CpG sites. After Bonferroni adjustment, a total of 2,324 CpG sites significantly differed in methylation level, with 684 CpG sites significantly hypermethylated and 1,640 hypomethylated in tumor, compared to nontumor tissues. Array data were validated with pyrosequencing in a subset of five of these genes; correlation coefficients ranged from 0.92 to 0.97. Analysis of plasma DNA from 38 cases demonstrated that 37%-63% of cases had detectable hypermethylated DNA (≥5% methylation) for these five genes individually. At least one of these genes was hypermethylated in 87% of the cases, suggesting that measurement of DNA methylation in plasma samples is feasible. Conclusion: The panel of methylated genes indentified in the current study will be further tested in a large cohort of prospectively collected samples to determine their utility as early biomarkers of HCC.

1 May 2000 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
CCChien‐Jen Chen
Chien‐Jen Chen
LWLi‐Yu Wang
Li‐Yu Wang
MYMing-Whei Yu
Ming-Whei Yu